Observational studyAnnals of hematology2024

Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression.

Max J Rieger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.